Halozyme beats Q2 with $231M revenue, $0.91 non-GAAP EPS; reiterates raised 2024 outlook

HALOZYME THERAPEUTICS, INC.

2024-Q2 EPS reported $1.32 revenue$427,232,000

Revenue $231M (+5% YoY), net income $93M (+24%), GAAP EPS $0.72, non-GAAP EPS $0.91.
Royalty revenue $124.9M (+12% YoY) led by Phesgo, VYVGART Hytrulo, and Teriparatide launches.
Reiterated FY2024 guidance: rev $935-1015M, adj EBITDA $555-615M, non-GAAP EPS $3.65-4.05.
Partner approvals: Ocrevus SC (EU/UK), VYVGART Hytrulo for CIDP (US); BMS nivolumab SC PDUFA Dec 29, 2024.
Completed $250M ASR (6.5M shares at $38.35); new EU patent extends ENHANZE royalty through March 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.